Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of mifepristone and cell lines, which is applied in the field of cell lines, can solve the problems of reducing the tumor formation of ES cell transplantation, and achieve the effects of reducing the risk of tumor formation, maintaining curative effect, and improving safety
Inactive Publication Date: 2012-04-25
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, there is no report about the transfer of caspase-1 into ES cells, which not only maintains the efficacy of ES therapy, but also reduces the risk of ES cell transplantation into tumors.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0053] Example 1 Caspase-1 expression by mimetricone expresses the tumor formed by the formation of embryo stem cells
[0054] 1. Experimental purpose
[0055] Caspase-1 belongs to one of the inflammatory cysteension, which can cause inflammatory cell death after activation.Excessive expression in the body can also cause tumor cell death.After Caspase-1 activation, it can induce the firing membrane to form fine pores to enters the cells, causing permeability to dissolve; leading to the release of CASPASE-1 related cytokines such as IL-18 and IL-18;Unknown nucleotide cutase shear DNA.So we choose this gene as the killing gene.
[0056] By introducing the Geneswitch technology platform in ES cells, constructing a caspase-1 expression system for meterone-regulated, and observing the use of Mepitetanone treatment in vitro and in vivo situations in vitro and in vivo.The impact of tumor cells.
[0057] 2. Materials and methods
[0058] 1. The main reagents and materials
[0059] BSA, 5 ...
Embodiment 2
[0120] Example 2 Caspase-1 expression by meterone-1 expression clearing tumors formed by internal end brain embryo stem cells without removing transplanted dopamine neurons
[0121] 1. Experimental purpose
[0122] Study using Caspase-1-ES cells regulated by Mikfidone, tumor cells formed by ES cells are eliminated while reserving dopamine neurons formed by ES cell differentiation.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
thickness
aaaaa
aaaaa
Login to view more
Abstract
The invention relates to a caspase-1-ES cell line induced by mifepristone. The collection number of the caspase-1-ES cell line is CCTCC No.C201193. The invention also provides a preparation method and application of the cell line. The invention has the advantages that: caspase-1 is transferred into an embryonic stem (ES) cell for the first time, and the differential potential of the cell is not influenced; the caspase-1 is highly expressed in the ES cell for the first time, it is proved that activated caspase-1 initiates DNA damage to cause death of undifferentiated caspase-1-ES cells in vitro, and a risk of nodule formation caused by ES cell transplantation is reduced; it is discovered that the highly expressed caspase-1 in the differentiated ES cell does not obviously influence the cell for the first time, and the treatment effect of the ES cell is maintained; and the safety of embryonic stem cell transplantation is improved, the effect of treating parkinson disease and other neurologic diseases is remained, and the caspase-1-ES cell line can be widely applied to stem cell transplantation.
Description
Technical field [0001] The invention involves a cell line. Specifically, it is a Caspase-1-ES cell line and its preparation methods and applications induced by Mepatone. Background technique [0002] Parkinson ’s Disease (PD) is the second common nervous system transgender disease in the second place. Its pathological characteristics are mainly manifested by the loss of black dopamine neurons and the formation of Louis small body.Commonly used treatment strategies are only limited to symptomatic treatment and minimize the clinical symptoms of patients. Such treatment methods cannot fundamentally reverse the occurrence and development of PD.Embryonic STEM Cells (ES cells) are cells with a variety of differentiation potential and can induce differentiation into specific cell types. This characteristic makes it have a broad prospect in cell replacement therapy.ES cell transplantation is expected to be applied to the treatment of PD, but a small amount of ES cells mixed with transpla...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more